HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair
Carcinogenesis · 21.11.2025 · 46 (4)
DOI: 10.1093/carcin/bgaf070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, online erschienen am 15.10.2025. Verfasst von Weiqi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Avenue, Nanchang 330006, Jiangxi Pr…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiation Tolerance, DNA Repair, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of China, Hansoh Cancer Research Fund Project of the Beijing CSCO Clinical Oncology Research Foundation, Committee of Jiangxi Natural Science Foundation Committee.
Abstract (Originalsprache)
Nonsmall cell lung cancer (NSCLC) harboring EGFR mutations, including the resistant T790M variant, continues to require improved therapeutic strategies despite the development of EGFR tyrosine kinase inhibitors (TKIs). This study evaluates the radiosensitizing potential of HS-10296 (almonertinib), a third-generation EGFR-TKI, in EGFR-mutant NSCLC models. In vitro studies demonstrated selective growth inhibition in mutant cells (PC-9: half-maximal inhibitory concentration (IC50) = 2.62 μM; H1975: IC50 = 5.22μM at 48 h) compared to wild-type A549 cells (IC50 = 11.42 μM). Clonogenic assays revealed significant radiosensitization in mutant cells (SER: PC-9 = 1.22; H1975 = 1.55) through multiple mechanisms including enhanced DNA damage (1.5–2.0-fold increase in comet tail moments with 4–10× persistent γH2A.X foci), marked suppression of RAD51-mediated DNA repair, and increased apoptosis (combination therapy: 19.53%–20.71% versus monotherapies: 12.08%–14.05%). Mechanistic investigation showed HS-10296 attenuated phosphorylation of EGFR and downstream effectors AKT and ERK, potentially disrupting DNA damage response pathways. In vivo validation using H1975 xenografts demonstrated superior tumor growth inhibition with the combination of HS-10296 and radiotherapy, which correlated with reduced expression of p-EGFR, p-AKT, and RAD51, along with increased γH2A.X levels. These findings establish HS-10296 as a promising radiosensitizer for EGFR-mutant NSCLC through simultaneous targeting of oncogenic signaling via PI3K/AKT and MAPK/ERK pathways and critical DNA repair mechanisms. The study provides compelling preclinical evidence supporting clinical evaluation of HS-10296 combined with radiotherapy for EGFR-driven NSCLC, including tumors with T790M-mediated resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Avenue, Nanchang 330006, Jiangxi Province, PR China.
- Department of Respiratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Avenue, Nanchang 330006, Jiangxi Province, PR China.
- Department of Respiratory, People's Hospital of Baoan District, Shenzhen, 118 Longjing 2nd Road, Xin'an Street, Bao'an District, Shenzhen 518101, Guangdong Province, PR China.
ORCID-Profile: Weiqi Liu, Yulian Liu, Yun Xie, Hui Huang, Mengzhi Wan, Ling Zhou, Fei Xu, Min Zhong
Förderung
- Natural Science Foundation of China
- Hansoh Cancer Research Fund Project of the Beijing CSCO Clinical Oncology Research Foundation
- Committee of Jiangxi Natural Science Foundation Committee
- Jiangxi Traditional Chinese Medicine Science and Technology Program
- Science and technology project of Health and Family Planning Commission of Jiangxi Province
- Beijing kechuang tumor diseases of medical development foundation projects
- Nanchang university education development foundation "Chang Yi Ling Yan" clinical research subject
- Nanchang university education development foundation “Chang Yi Ling Yan” clinical research subject
Zitieren
APA
Liu, W., Liu, Y., Xie, Y., Huang, H., Wan, M., Zhou, L., Xu, F., & Zhong, M. (2025). HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair. Carcinogenesis, 46(4). https://doi.org/10.1093/carcin/bgaf070
Vancouver
Liu W, Liu Y, Xie Y, Huang H, Wan M, Zhou L, et al. HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair. Carcinogenesis. 2025;46(4). doi:10.1093/carcin/bgaf070
BibTeX
@article{Liu2025,
author = {Liu, Weiqi and Liu, Yulian and Xie, Yun and Huang, Hui and Wan, Mengzhi and Zhou, Ling and Xu, Fei and Zhong, Min},
title = {HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair},
journal = {Carcinogenesis},
year = {2025},
volume = {46},
number = {4},
doi = {10.1093/carcin/bgaf070}
}
EUVIMED